Major Depressive Disorder

Carmen Kosicek, MSN, PMHNP-BC, shares tips with patients about the use of zuranolone to treat MDD.

Due to ethical, knowledge, cost, and acceptability issues, deep brain stimulation is underutilized in disease states like treatment-resistant schizophrenia.

Experts in psychiatry review adverse effects of zuranolone, a γ-aminobutyric acid (GABA) receptor modulator, in the treatment of MDD.

Roger S. McIntyre, MD, FRCPC, comments on the paradigm shift of the frequency of dosing in the treatment of MDD, highlighting GABAergic modulating treatments, as well as the use of therapy to improve mental health.

Does early improvement in insomnia predict response to pharmacotherapy in psychotic depression? Authors performed a secondary analysis of a randomized clinical trial.

Carmen Kosicek, MSN, PMHNP-BC, shares considerations on the perception of mental health treatment among diverse cultures and ages within the United States.

Experts in psychiatry comment on the use of GABAa receptor modulators in the treatment of major depressive disorder (MDD), highlighting zuranolone.

From new research on treatment-resistant major depression to strategies for supporting trauma-affected refugee youth, here are highlights from the week in Psychiatric Times.

What is new in research on depression?

“Over 32 weeks of follow-up, the percentage of patients with remission, the percentage of patients with a treatment response, and the change in the MADRS score from baseline favored esketamine nasal spray.”

Roger S. McIntyre, MD, FRCPC; and Carmen Kosicek, MSN, PMHNP-BC; review the mechanism of action of newer therapies in MDD treatment.

Roger S. McIntyre, MD, FRCPC; and Carmen Kosicek, MSN, PMHNP-BC, discuss provider and patient communication about the time to onset of action of major depressive disorder (MDD) treatments and when the patient can expect to see a difference.

Get ready for our upcoming virtual, interactive conference with some highlights from 2022.

Is psilocybin a viable treatment for MDD? Researchers performed a phase 2, double blind trial of single-dose psilocybin in patients with treatment resistant depression.

From connections between cannabis use and schizophrenia to some non-psychiatric medications that may worsen symptoms of major depression, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of September.

Following a long path to approval, gepirone hydrochloride extended-release tablets (Exxua) is the first FDA-approved medication with this novel mechanism of action for adults with MDD.

Roger S. McIntyre, MD, FRCPC, discusses the history of psychiatry and the conventional treatment and response times, leading into the current treatment armamentarium for treatment of major depressive disorder (MDD).

Carmen Kosicek, MSN, PMHNP-BC, reviews the definition of “rapid-acting” therapies as well as their role in treating major depressive disorder (MDD).

The ongoing clinical trial is also studying the drug’s efficacy in the treatment of MDD.

In this CME article, get a better understanding of bleeding risk associated with use of serotonin reuptake inhibitors (SRIs) and review research-informed literature on related bleeding complications in patients with cardiovascular and cerebrovascular disease.

“Are my other medications making my depression worse?” Researchers investigated associations between medications with potential depressive symptom adverse effects and the level of depressive symptoms in a large survey study.

From violence risk assessment in emergency departments to connections between bipolar disorder and substance use disorders, here are highlights from the week in Psychiatric Times.

The investigators noted fast, clinically meaningful, and sustained improvements in symptoms of depression and related functional impairment.

Do SSRIs impact on the antidepressant efficacy of psilocybin? Researchers performed an open-label trial of single-dose psilocybin in patients with TRD who were taking SSRIs.